How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,087 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system

been accredited by NICE). The NICE guideline on Long-acting reversible contraception offers best-practice advice for all women of reproductive age who may wish to regulate their fertility by using copper intrauterine devices, progestogen-only intrauterine systems (Mirena) and progestogen-only injectable contraceptives (intramuscular depot medroxyprogesterone acetate, Depo-Provera and norethisterone enantate, Noristerat). The progestogen-only subdermal implant, Implanon, recommended in the guideline (...) be considered first-line £7.95 to £27.11 c Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41) © NICE 2018. All rights reserved. Subject to Notice of rights ( conditions#notice-of-rights). Page 16 of 20Etonogestrel implant (Nexplanon) 68 mg subdermal implant for up to 3 years £79.46 a Intramuscular depot medroxyprogesterone acetate (Depo- Provera) 150 mg/ml intramuscular injection every 12 weeks (±5 days) £6.01 c Subcutaneous

2014 National Institute for Health and Clinical Excellence - Advice

42. Mobile phone-based interventions for improving contraception use. Full Text available with Trip Pro

an intervention comprising automated interactive voice messages and phone counsellor support (RR 1.39, 95% CI 1.17 to 1.66).One feasibility trial in the USA reported a lower mean number of days between scheduled and completed attendance for the first but not subsequent Depo-Provera appointments using clinic records from an intervention comprising reminders and healthy self management text messages (mean difference (MD) -8.60 days, 95% CI -16.74 to -0.46). Simple text message OC reminders had no effect

2015 Cochrane

43. Contraception - progestogen-only methods

causes changes in cervical mucus that inhibit sperm. When used perfectly (consistently and correctly), 0.05% of women will conceive within the first year of use due to method failure. The progestogen-only injectables contain depot medroxyprogesterone acetate (Depo Provera® and Sayana Press®) or norethisterone enantate (Noristerat®). Depo Provera® should be given by deep intramuscular injection every 12 weeks. Sayana Press® should be given by subcutaneous injection every 13 weeks. Noristerat® should

2019 NICE Clinical Knowledge Summaries

44. Postpartum family planning

) Breastfeeding women Male and female condoms Progestogen-only injectable (POI) contraceptives (Depo-Provera/NET-EN) Progestogen-only pills (POP) Male sterilisation Female sterilisation Contraceptive implants 6 months 12 months and beyond All women IUD 48 hours 4 days 7 days 3 weeks 4 weeks 6 weeksBest practice in postpartum family planning 5 Royal College of Obstetricians and Gynaecologists Best Practice Paper No. 1 The most effective methods These methods are generally associated with failure rates of less (...) users. Progestogen-only injectable (POI) contraceptives • Progestogen-only injectable (POI) contraceptives (Depo-Provera ® and norethisterone enanthate (NET-EN)) last 8–12 weeks and so repeat injections must be given four or more times each year, requiring the woman to return to a provider or be in contact with a community-based distributor. • Failure rates are around 3 per 100 users largely because of failure to get a repeat injection. • Amenorrhoea is common with these methods and the return

2015 Royal College of Obstetricians and Gynaecologists

45. Breast cancer - managing FH

on . Etonogestrel-only implant (Nexplanon ® ). For more information, see the CKS topic on . Depot medroxyprogesterone acetate (Depo-Provera ® , SAYANA PRESS ® ). For more information, see the CKS topic on . Progestogen-only pill (POP). For more information, see the CKS topic on . Combined hormonal contraceptives (CHC). For more information, see the CKS topic on . Inform women aged over 35 years with a family history of breast cancer that there is an increased risk of breast cancer associated with taking (...) be generally used (UKMEC category 2): POP. Depot medroxyprogesterone acetate (Depot-Provera ® , SAYANA PRESS ® ). Etonogestrel-only implant (Nexplanon ® ). LNG-IUS. If the CHC is being considered (UKMEC category 3), discuss with (or refer the woman to) a specialist genetics service, as views are conflicting on whether or not the protective effects of CHC against ovarian cancer outweigh the increased risk of breast cancer. Basis for recommendation Basis for recommendation These recommendations are based

2018 NICE Clinical Knowledge Summaries

46. Dysmenorrhoea

to an NSAID if the response is insufficient. See the CKS topic on for information on prescribing paracetamol. If the woman does not wish to conceive, consider prescribing a 3–6 month trial of a hormonal contraceptive as an alternative first-line treatment. Monophasic combined oral contraceptive (COC) preparations containing 30–35 micrograms of ethinylestradiol and norethisterone, norgestimate, or levonorgestrel are usually first choice. Oral (desogestrel 75 micrograms), parenteral (Depo-Provera ®

2018 NICE Clinical Knowledge Summaries

47. Birth control options: Things to consider

birth control options are available? Among your birth control options are: Barrier methods. Examples include male and female condoms, as well as the diaphragm, cervical cap and contraceptive sponge. Hormonal methods. Examples include birth control pills, as well as the vaginal ring (NuvaRing), contraceptive implant (Nexplanon), contraceptive injection (Depo-Provera) and birth control patch. Intrauterine devices (IUDs). Examples include the copper IUD (ParaGard) and the hormonal IUD (Mirena, Skyla

2019 OHRI

48. Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels. Full Text available with Trip Pro

Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels. High usage of progestin-only injectable contraceptives, which include the intramuscular injectables depo-medroxyprogesterone acetate (DMPA-IM, Depo-Provera) and norethisterone (NET) enanthate (NET-EN or Nur-Isterate), correlates worldwide with areas

2018 PLoS ONE

49. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

Type 2 Growth hormone deficiency Hypercortisolism Hyperparathyroidism Hyperthyroidism Hypogonadism Hypophosphatasia Porphyria Pregnancy Alcoholism Anorexia nervosa Calcium deficiency Chronic liver disease Malabsorption syndromes/ malnutrition (including celiac disease, cystic fibrosis, Crohn’s disease, and gastric resection or bypass) Total parenteral nutrition Vitamin D deficiency Antiepileptic drugs a Aromatase inhibitors Chemotherapy/ immunosuppressants Depo-Provera Glucocorticoids Gonadotropin

2016 American Association of Clinical Endocrinologists

51. What can be done to help heavy periods?

and medroxyprogesterone acetate are taken on a cyclical basis. They can be effective at reducing blood loss and at helping to regulate the menstrual cycle. Long term they are often unacceptable because of their side effects such as bloating, headache, breast tenderness and breakthrough bleeding. The contraceptive injection (eg Depo-Provera) may stop periods altogether but it is not licensed as a treatment for menorrhagia. The combined oral contraceptive pill can often diminish menstrual loss although there is little

2016 Evidently Cochrane

52. Contraception During Breastfeeding

: progestin-only options There is theoretical concern related to milk supply when progesteroneoptionsareinitiatedintheinitial48hoursafter delivery 24 as a drop in progesterone levels after birth is necessary for secretory differentiation/lactogenesis II to occur. Progestin-containing contraceptives include the progestogen-only pill (‘‘minipill’’) as well as contraceptive implants such as Nexplanon (Merck & Co.), Depo- Provera (depot medroxyprogesterone acetate [DMPA]; P?zer,NewYork,NY (...) postpartum period is contradictory and insuf?cient. COC, combined oral contraceptive; DMPA, depo-medroxyprogesterone acetate; IUD, intrauterine device; LNG, levonorgestrel. 5 hormonalmonitoring,andthencouplesabstainduringfertile periods. All of these methods have speci?c protocols for womentouseduringthepostpartumperiodsotheymayplan accordingly if they wish to delay another pregnancy. The Marquette model has a recent peer-reviewed study to show the ef?cacy of its postpartum protocol. 18 These methods may

2015 Academy of Breastfeeding Medicine

54. In the name of science: Ethical violations in the ECHO randomised trial. Full Text available with Trip Pro

In the name of science: Ethical violations in the ECHO randomised trial. It was in the 1990s, that the possibility of increased transmission of HIV with the use of injectable contraceptive Depo-Provera®, was first flagged in medical literature. This has posed a challenge for its use in countries, particularly in the African region, where the prevalence and transmission rate of HIV is high. In 2015, a randomised 'clinical' trial, the Evidence for Contraceptive Options and HIV Outcomes (ECHO

2019 Global public health Controlled trial quality: uncertain

55. The Effects of Alcohol Consumption on Central Adiposity

Serious digestive disorders Conditions that affect metabolism or body weight (i.e. uncontrolled thyroid conditions, bariatric surgery, pregnancy, breastfeeding) Partial and/or full hysterectomy Hormonal pharmaceutical contraceptives including oral contraception (birth control pills), injectables (Depo-Provera), or the patch (Xulane) PCOS Use of medications that affect body weight or metabolism (i.e. atypical antipsychotics, weight loss medications). Not willing to store biospecimens for future use

2018 Clinical Trials

56. People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

, an intrauterine device, Depo-Provera, or Norplant until 12 weeks post therapy. Current or prior history of any of the following: Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded. Gastrointestinal disorder or post-operative condition that could interfere

2018 Clinical Trials

57. Single Hormone Closed Loop Study With PDT Sensor

contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non

2018 Clinical Trials

58. Olaparib in People With Malignant Mesothelioma

Intrauterine Device PLUS male condom. Provided coils are copper-banded. Etonogestrel implants (e.g., Implanon , Norplant ) PLUS male condom Normal and low dose combined oral pills PLUS male condom Hormonal shot or injection (e.g., Depo-Provera) PLUS male condom Intrauterine system device (e.g., levonorgestrel-releasing intrauterine system -Mirena ) PLUS male condom Norelgestromin/ethinyl estradiol transdermal system PLUS male condom Intravaginal device (e.g., ethinyl estradiol and etonogestrel) PLUS male

2018 Clinical Trials

59. AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)

and have a negative urine pregnancy test result. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception

2018 Clinical Trials

60. Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301

of contraception between the 2 visits. Approved forms of contraception include hormonal intrauterine devices, hormonal contraceptives (oral birth control pills, Depo-Provera®, patch, or other injectables) together with supplementary double-barrier methods, such as condoms or diaphragms with spermicidal gel or foam. The following categories define females who are NOT considered to be of childbearing potential: Premenopausal females with 1 of the following: Documented hysterectomy, Documented bilateral

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>